Home | Welcome to Contract Pharma   
Last Updated Thursday, April 24 2014
Print

Synteract To Acquire HCR



Published December 20, 2012
Related Searches: Phase II CRO Development Clinical Trials
Synteract, a portfolio company of Gryphon Investors, has entered into a definitive agreement to acquire Harrison Clinical Research (HCR), headquartered in Munich, Germany, with operations in Europe, Israel and South America, and Princeton, NJ. Synteract plans to combine operations to become a global service provider. The transaction, subject to customary closing conditions, is expected to close in 1Q13.
 
Through the acquisition, Synteract gains a clinical in-patient unit in Germany and a clinical research training center in Belgium, as well as early phase and clinical pharmacology services, Phase II-IV capabilities, and a functional service provision.
 
Wendel Barr, Synteract’s chief executive officer, will lead the combined companies. Dr. Francisco Harrison, HCR’s chairman and founder, will remain a senior member of the executive team and become a member of the board of directors. The HCR management will remain in place.
 
“Harrison Clinical Research is an exceptional fit for Synteract, uniting two well-respected players with longstanding drug development expertise to form a new global leader with enhanced scale and therapeutic breadth,” said Mr. Barr. “Together we will provide a continuum of service that allows us to work with clients throughout their entire development life cycle, from emerging products through post-marketing.”
 
Dr. Harrison added, “HCR has a long tradition of outstanding customer service, as does Synteract. We see this as a growth opportunity that allows us to continue providing our customers with the same personalized service they have come to expect, but on a larger geographic scale. Our shared company cultures and flexible, customizable approaches to managing clinical trials make this a natural fit for us and ensure our clients will continue receiving the same expertise and excellent customer service worldwide.”

Fairmount Partners, through managing director Neal McCarthy, represented Synteract in a focused acquisition search and on the transaction with Harrison Clinical Research.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On